Aclaris Therapeutics (ACRS) Capital Expenditures (2014 - 2026)
Aclaris Therapeutics' (ACRS) quarterly Capital Expenditures came in at $60000.0 in Q1 2026, up 39.53% year-on-year from $43000.0 in Q1 2025, and down 39.39% quarter-over-quarter from $99000.0 in Q4 2025.
Aclaris Therapeutics (ACRS) Capital Expenditures (2014 - 2026) Analysis & Trends
Aclaris Therapeutics' Capital Expenditures history runs 13 years deep, the most recent figure standing at $60000.0 for Q1 2026.
- On a quarterly basis, Capital Expenditures rose 39.53% year-over-year to $60000.0 in Q1 2026; TTM through Mar 2026 was $128000.0, a 341.38% increase from a year earlier, with the FY2025 full-year figure at $111000.0, down 8.26% from the prior year.
- Capital Expenditures slipped to $60000.0 in Q1 2026 per ACRS's latest filing, from $99000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $933000.0 in Q4 2023 and bottomed at -$476000.0 in Q4 2022.
- The 5-year median for Capital Expenditures is $60000.0 (2026), against an average of $108333.3.
- Across the five-year window, Capital Expenditures slumped 338.0% in 2022 and jumped 296.01% in 2023, its largest moves.
- Year by year, Capital Expenditures stood at -$476000.0 in 2022, then soared by 296.01% to $933000.0 in 2023, then tumbled by 101.5% to -$14000.0 in 2024, then jumped by 807.14% to $99000.0 in 2025, then sank by 39.39% to $60000.0 in 2026.
- Per Business Quant, the three latest ACRS Capital Expenditures figures stand at $60000.0 (Q1 2026), $99000.0 (Q4 2025), and -$52000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Aclaris Therapeutics | 705.88 Mn | 705.88 Mn | 1.60 Mn | 60,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 60,000.00 |
| Mar 31, 2026 | 60,000.00 |
| Dec 31, 2025 | 99,000.00 |
| Dec 31, 2025 | 99,000.00 |
| Sep 30, 2025 | -52,000.00 |
| Sep 30, 2025 | -52,000.00 |
| Jun 30, 2025 | 21,000.00 |
| Jun 30, 2025 | 21,000.00 |
| Mar 31, 2025 | 43,000.00 |
| Mar 31, 2025 | 43,000.00 |
| Jun 30, 2024 | -14,000.00 |
| Jun 30, 2024 | -14,000.00 |
| Mar 31, 2024 | 135,000.00 |
| Mar 31, 2024 | 135,000.00 |
| Dec 31, 2023 | 933,000.00 |
| Dec 31, 2023 | 933,000.00 |
| Sep 30, 2023 | -18,000.00 |
| Sep 30, 2023 | -18,000.00 |
| Jun 30, 2023 | 353,000.00 |
| Jun 30, 2023 | 353,000.00 |